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Alport syndrome inevitably leads to end-stage renal disease
and there are no therapies known to improve outcome. Here
we determined whether angiotensin-converting enzyme
inhibitors can delay time to dialysis and improve life
expectancy in three generations of Alport families. Patients
were categorized by renal function at the initiation of therapy
and included 33 with hematuria or microalbuminuria,
115 with proteinuria, 26 with impaired renal function, and
109 untreated relatives. Patients were followed for a period
whose mean duration exceeded two decades. Untreated
relatives started dialysis at a median age of 22 years.
Treatment of those with impaired renal function significantly
delayed dialysis to a median age of 25, while treatment of
those with proteinuria delayed dialysis to a median age of 40.
Significantly, no patient with hematuria or microalbuminuria
advanced to renal failure so far. Sibling pairs confirmed these
results, showing that earlier therapy in younger patients
significantly delayed dialysis by 13 years compared to later or
no therapy in older siblings. Therapy significantly improved
life expectancy beyond the median age of 55 years of the
no-treatment cohort. Thus, Alport syndrome is treatable
with angiotensin-converting enzyme inhibition to delay
renal failure and therapy improves life expectancy in a
time-dependent manner. This supports the need for early
diagnosis and early nephroprotective therapy in
oligosymptomatic patients.
Kidney International (2012) 81, 494–501; doi:10.1038/ki.2011.407;
published online 14 December 2011
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Evaluation of microhematuria and microalbuminuria is
common in everyday clinical practice as they are impor-
tant early signs for chronic kidney disease (CKD). CKD
substantially increases the risk of cardiovascular events
and death.1 Renal fibrosis is the end point of most CKDs.
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Therefore, in addition to controlling hypertension,2 therapy
targeted at the prevention of renal fibrosis may be of value.
Renal fibrosis due to Alport syndrome (AS) is seen in
association with end-stage renal disease (ESRD) in children
and young adults.3 AS is a hereditary nephropathy character-
ized by progressive renal failure, sensorineural deafness, and
typical ocular changes.4 AS serves as a model of understanding
progression of chronic renal fibrosis in mice5–7 and humans.8
The disease is caused by mutations in type IV collagen genes,
leading to an abnormal composition of the glomerular
basement membrane.9 In all, 85% of Alport families have an
X-chromosomal and 15% an autosomal trait of inheritance.10
Abnormal composition of the glomerular basement mem-
brane due to AS leads to extensive matrix deposition,
inflammation, and fibrosis.5,6 These are major components
of progressive renal failure in literally all CKDs. AS inevitably
leads to ESRD during adolescence or early adulthood, and
B50% of patients develop ESRD by the age of 20 years.11
Early diagnosis in children with AS with isolated hematuria
opens a ‘window of opportunity’ for early intervention.
Currently, there are no causal therapeutic options that are
proven to delay renal failure in AS.8 Angiotensin-converting
enzyme inhibition (ACEi) has been shown to reduce
proteinuria in Alport patients12 and to delay renal failure in
Alport mice,5 suggesting that it may be of value as an effective
treatment to delay renal failure in humans.7 To test this we
established the European Alport Registry to collect data over
several generations of Alport families across Europe. Small
children with AS first develop microscopic hematuria,
proceeding to microalbuminuria, overt proteinuria, and
impaired renal function, and end up with ESRD. These
different steps of disease enabled us to assess if earlier
introduction of ACEi at earlier degrees of disease is more
effective than later therapy in delaying the time to dialysis and
improving life expectancy. Our results might have the
potential for generalization of the use of early nephroprotec-
tive therapy in all patients with Alport syndrome in everyday
clinical practice.
RESULTS
Primary end point ‘age at start of renal replacement therapy’
A total of 283 patients were followed for a mean of more than
two decades (Figure 1). The mode of inheritance was within
the expected range (Table 1).10
All 109 noT patients (red curve, Figure 2) were related to
treated patients. Because of the genotype–phenotype correla-
tion in AS,3 the noT group with the same genotype mini-
mized selection bias toward ‘more benign’ mutations in the
573 Individuals in European Alport Registry
with kidney biopsy and/or mutation analysis
297 Patients
(X-chrom. hemizygous or
autosomal homozygous)
283 Grouping
treated patients plus their untreated relatives
109 noT
untreated
Statistical analysis Statistical analysis
15 Sibling pairs
Figure 3
Onset of end-stage
renal failure
Figure 2
Life-expectancy
Figure 4
Side effects
14 reported in 278
treated patients/carriers
(missing data in 6)
33 T-I
hematuria or
microalbuminuria
115 T-II
proteinuria
Updating of the primary data set
Spring 2010
26 T-III
impaired renal function
23 Excluded
8 lost of follow-up, 6 diagnosis not
confirmed, 3 additional therapy, 2 additional
disease, 4 noncompliance to therapy
276 Carriers
(X-chrom. heterozygous or
autosomal rec. heterozygous)
157 Untreated
carriers
110 Treated
carriers
Figure 1 | Screening, assignment, follow-up, and selection for statistical analysis. Work flow of screening, assignment, updating data,
and statistical analysis of Alport syndrome (AS) patients. Heterozygous carriers of Alport mutations were included in analysis of side
effects of medication, but excluded from all other analyses. X-chrom., X-chromosomal.
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therapy groups. The median age at onset of renal replacement
therapy (RRT) in noT was 22 years (range and confidence
intervals are shown in Table 1). T-III (n¼ 26) had a median
age at onset of ACEi therapy of 20 years and a mean duration
of ACE inhibition of 7.4 years. T-III delayed median age at
onset of RRT by 3 years to 25 years (yellow curve, Figure 2;
Po0.001 vs. noT). T-II (n¼ 115) had a median age at onset
of ACEi therapy of 13 years and a mean duration of ACEi
therapy of 5.8 years. T-II delayed median age at onset of RRT
by 18 years to 40 years (green curve, Figure 2; Po0.001 vs.
noT). T-II was more effective than T-III (Po0.001). T-I
(n¼ 33) had a median age at onset of ACEi therapy of 8 years
and a mean duration of ACEi therapy of 4.0 years. None of
the patients yet reached CKD stages X3 (blue curve,
Figure 2). T-I was more effective than noT (Po0.001) and
T-II (Po0.001; P¼ 0.19 vs. T-III).
Verification of superior outcome of earlier therapy
in sibling pairs
In order to address any selection bias, we assessed the effect
of introducing ACEi at an earlier stage of disease by
comparing 15 sibling pairs (Figure 3; Table 1). Each pair
had the same mutation, and lived in the same environment.
Typically, the older brother within these families was
diagnosed quite late in the course of AS. However, diagnosis
in this older sibling classically enabled earlier diagnosis in the
other (younger) sibling, allowing for intervention with
medication in the younger sibling at an earlier stage of
disease (Table 1). The results showed that the median age at
onset of RRT in the older sibling was 27 years compared with
a median age at onset of RRT of 40 years in the younger
(Po0.001).
Primary end point ‘life expectancy’
Life expectancy of 101 noT patients was compared with 174
treated patients (T-I, -II, and -III). Patients who died because
of limited access to RRT were excluded. The numbers of
events in the T-I, -II, and -III groups were too low for
statistical comparison between therapy groups. Median life
expectancy of noT patients (solid curve, Figure 4) was 55
years; lifespan was found to be significantly improved by
ACEi (dashed curve, Figure 4; P¼ 0.0369 vs. noT) in the
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Figure 2 |Age at onset of renal replacement therapy in
different treatment modalities. Untreated patients (red curve)
are relatives to the treated patients (yellow, green, and blue
curves) and have the same genotype. Angiotensin-converting
enzyme (ACE) inhibition delays renal failure in a time-dependent
manner. Tick marks indicate censoring data. Kaplan–Meier
estimate.
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Figure 3 |Age at onset of renal replacement therapy (RRT):
verification of superior outcome of earlier therapy in sibling
pairs. Effect of different onset of therapy in 15 sibling pairs with
identical mutations and environment. Diagnosis in the older child
classically enabled earlier diagnosis in the other (younger) sibling,
resulting in earlier therapy. Earlier therapy delayed onset of RRT
by 13 years. Tick marks indicate censoring data. Kaplan–Meier
estimate.
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Figure 4 | Effect of treatment on life expectancy. Untreated
patients (solid line) are relatives to the treated patients (dashed
line) and have the same genotype. Angiotensin-converting
enzyme (ACE) inhibition improves life expectancy (P¼ 0.0369 vs.
noT). Tick marks indicate censoring data. Kaplan–Meier estimate.
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log-rank test. Both Figures 2 and 4 contain censored data
(because of their age or slow progression of disease, patients
drop out without the event RRT in Figure 2 and without the
event ‘death’ in Figure 4).
Parameters affecting renal outcome
The natural course of AS is reflected in our levels of disease
leading to therapy groups. Therefore, parameters such as
proteinuria and creatinine clearance showed an effect on renal
outcome. Hypertension usually occurs late in the course of
AS. Thus, hypertension was a late result of CKD stage 4 and
not an early predictor for poor renal outcome in AS (Table 1).
Data on blood pressure control during treatment in these
groups were not sufficient for statistical evaluation as
independent risk factors in the progression of Alport CKD.
As the study only included hemizygous X-chromosomal
males or homozygous autosomal patients, gender and mode of
inheritance were not predictors for renal outcome. The
number of in-frame vs. frameshift mutations was too low in
each group for statistical comparison. Year of birth was not
an independent predictor for renal outcome (but affected
inclusion to groups, Table 1).
Proteinuria initially decreased by a similar extent in all
therapy groups (Table 1). However, in T-II and T-III,
proteinuria typically climbed back to previous levels with
time. In contrast to those who received therapy later, patients
in T-I were less likely to return to pretreatment levels (31.3%,
10/32), and 12.5% (4/32) even stepped back in the course of
disease and reversed to the isolated hematuria level. Thus,
earlier therapy was found to be more effective than later
therapy to hold—or even reverse—the natural course of
proteinuria in Alport disease.
Side effects associated with medication
Side effects of the medication were reported in 14/278 (5.0%)
of patients and treated carriers (missing data in 6/284; 2.1%).
No severe side effects such as death from all causes, acute
renal failure, or angioedema were reported, neither in the
initial questionnaire nor in the data update in spring 2010.
Side effects included hyperkalemia o5.5mmol/l in 1.8%
(5/284), dry cough in 0.7% (2/284), symptomatic hypoten-
sion and fatigue in 0.7% (2/284), oral ulcers, polyuria and
polydipsia, aggressive behavior and agitation, sleep disorder,
and withdrawal because of ‘ineffectiveness’ each in 0.4%
(1/284 each).
DISCUSSION
The study reveals the first therapeutic option for Alport
patients with progressive renal fibrosis: ESRD can be delayed
by ACEi in a time-dependent manner, the earlier the better.
For the first time, our data show that preserving renal
function also results in a better life expectancy in patients
with CKD. Thus, our observation in a rare model disease
brings previous findings on the broad use of nephroprotec-
tion for everyday clinical practice in more common kidney
diseases to an end; preventing microalbuminuria in diabetes
in the BENEDICT trial,13 later intervention in the REIN and
RENAAL trials,14,15 and even after onset of RRT16 might
improve life expectancy. Our data support the general need
for early diagnosis and preventive therapy in CKD in yet
oligosymptomatic patients with more common diseases
including diabetes and hypertension.
Prospective analysis of treatment effects in AS seemed to
be impossible in a disease that needs additional 20 years until
ESRD develops. However, as a compromise, our European-
wide longitudinal observational effort is believed to have a
high quality, as (1) the study focuses on an easily verifiable
primary end point in a well-defined disease always leading to
ESRD; (2) age at onset RRT can be remembered exactly by
family members, minimizing the lack of data on affected
relatives; (3) this end point is most relevant for the children
concerning their quality of life, social life, and life expectancy;
and (4) as this end point is central to parents and
nephrologists, all—irrespective their diverse languages and
cultures—are willing to combine their personal destinies in
order to find a cure for AS. These advantages are reflected in
the high number of multinational participants, the high
percentage of updated patient data, the high compliance to
therapy (similar to the ESCAPE trial17,18), and the low rate of
‘loss of follow-up.’ Despite these advantages, our observa-
tional study design has the hazards of dropping relevant
information on side effects and of a selection bias by ‘picking’
the best patients from each country with a less severe
genotype into therapy groups leading to a better outcome.
The high number of patients in T-II reduces the risk of
a selection bias. The median age at onset of RRT in noT
(22 years) is close to the median age at onset of therapy T-III
(20 years). Therefore, we cannot exclude a selection bias. We
reduce the risk by using: (1) a long average time on therapy
(4.3 years in the T-III patients with the end point ESRD);
(2) similar generations (mean year of birth does not differ
significantly between groups noT and T-III, Table 1);
(3) untreated relatives as ‘intrafamilial controls’; (4) sibling
pairs; (5) by our multinational effort including treatment
data from 310 centers; and (6) by the final update of the
primary data set.
Proteinuria decreased in all therapy groups; however,
during the course of therapy, proteinuria returned back to or
even above the level before onset of therapy in the later
therapy groups, similar to the ESCAPE trial.17 Analogous to
animal models,6–8 only early therapy was capable to prevent
or reverse albuminuria in our patients. Blood pressure
influences the time point of ESRD in CKD.19 Inhibition of
the renin-angiotensin system has been previously shown to
delay ESRD in both diabetic and nondiabetic proteinuric
patients.20–23 However, the renoprotective effect of intensified
blood pressure control is additive to the benefit conferred by
ACE inhibitors in children in the ESCAPE trial.17,18
Furthermore, an arterial pressure below the 90th percentile
is a predictor for better outcome in the strict blood pressure
control arm. In our trial, data on blood pressure control
during treatment in these groups were not sufficient for
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statistical evaluation as independent risk factors in progres-
sion of Alport CKD. Although previous trials well establish
the major role of ACE inhibitors in lowering blood pressure
and delaying renal failure, our study demonstrates the
nephroprotective effects of ACE inhibitors even decades
before overt hypertension develops. As ACE inhibitors are
off-label use in normotensive children, safety issues become a
major concern. No serious adverse events were reported in
our study and the rate of side effects was rather low. However,
future prospective trials must focus on (1) the risk–benefit
balance of early therapy in oligosymptomatic children with
AS and (2) prognostic factors to evaluate progression. Start-
ing in spring 2012, the randomized, prospective, placebo-
controlled EARLY PRO-TECT Alport phase III clinical trial
(EudraCT number 2010-024300-10) will help to answer these
questions and to find the optimal time point of an early start
of therapy in the Alport population.
ACE inhibitors are not a specific therapy for AS. The
nephroprotective effect of ACE inhibitors in yet oligosymp-
tomatic, nonhypertensive patients with AS can be explained
only incompletely by their antiproteinuric and antihyperten-
sive properties.12 Data from Alport animal models point to a
major role of altered composition of the glomerular
basement membrane (weakened because of the genetic
defect) and of podocytes, their cytoskeleton, and their
collagen receptors.24,25 ACE inhibitors seem to have a
superior potential to downregulate profibrotic factors in
the Alport animal model.4,5 Downregulation of profibrotic
factors—known to be global players in all human fibrotic
diseases—is independent from blood pressure and the
amount of proteinuria in Alport mice.4,5 In humans,
however, this mechanism of action in AS is still specula-
tive—further prospective trials should focus on this crucial
topic in order to learn about the general mechanisms of
organoprotection during fibrosis.
CKD substantially increases the risk of cardiovascular
events and death.1 Nearly one in every seven adults in the
United States has CKD, with an increase of 30% over the last
decade.26 The reduction of the rate of progression and
prevention of CKD is likely to have significant medical and
socioeconomic impact. In 2006, 440% of incident dialysis
patients in the United States had not previously seen a
nephrologist27 or been treated with either an ACE inhibitor or
an angiotensin receptor blocker. Furthermore, public aware-
ness of early kidney disease is as low as 3 to 8%.28 In contrast,
most Alport families are well aware of the 100% risk of renal
failure in their affected children. Their high compliance, early
diagnosis allowing preemptive therapy, and the low comor-
bidity make AS an ideal model to investigate the general use
of early nephroprotection in CKD.6–8 Age at onset of RRT in
Figures 2 and 3 clearly spreads out in favor of earlier therapy
in CKD. Similar findings from the Alport animal models
make obvious that preemptive therapy before onset of renal
damage (reflected by proteinuria) is most effective in delaying
renal failure and improving life expectancy in everyday
clinical practice for all physicians.
MATERIALS AND METHODS
Inclusion and exclusion criteria
The diagnosis of AS was proven by kidney biopsy or mutation
analysis (or both). Patients were included if they were affected males
with X-linked AS or patients with genetically proven homozygous
autosomal AS.9,11,29 Patients were excluded if they did not give
informed consent or the diagnosis was suspected but not confirmed.
Primary data collection in the European Alport Registry
and study design
Patient information, study protocol, questionnaire, consent form
(in English, French, Spanish, and German; see Supplementary
Material online), data collection, anonymization, and storage con-
form with good clinical practice guidelines were approved by the
Ethics Committee (AZ 10/11/06, see Supplementary Material online;
authorization of French data by the Commission Nationale de
l’Informatique et des Liberte´s 908249). Primary data were processed
by medical students, and data quality and accuracy was checked by
the lead investigator (OG) using telephone interviews, email,
facsimile, or by personal contact with both the physicians and
patients. Questionnaires included demographic data (age, gender,
country of origin, family history, and mode of inheritance) and
clinical and laboratory data (how the diagnosis was made, age at
onset of RRT, ACEi therapy and age at onset of therapy, renal para-
meters before and after onset of ACEi therapy such as proteinuria,
creatinine, creatinine clearance, cholesterol, hypertension, hearing
loss, eye symptoms, death from all causes, and side effects of
medications such as hyperkalemia, angioedema, renal failure, cough,
hypotension, rhabdomyolysis, and others).
The Registry retraces data from 310 participating centers on
several decades in three generations of AS patients, hindering a
prospective study design. Most pediatric nephrologists currently
treat their AS patients with ACE inhibitors,8 despite the fact that
ACE inhibitors are off-label use in nonhypertensive children. As a
consequence, following the concerns of the Ethics Committee and
the German Society of Pediatric Nephrology regarding the legal
aspects of any recommendation for this off-label use in children, this
study could not be registered as a trial, but was designed as a
noninterventional observational study investigating treatment
effects in a purely observational manner without affecting therapy,
its modality, or diagnostic decisions.
Screening, assignment, and follow-up
Screening, assignment, follow-up, and selection for statistical analysis
are described in Figure 1. Data were collected from Germany, France,
Spain, Belgium, Austria, Switzerland, United States (limited to only
those families who recently moved from Europe to United States),
Russia, Serbia, Romania, Italy, and Turkey. The primary data set was
updated exclusively in spring 2010 by the lead investigator to ensure
compliance to the Ethics Committee recommendations. Data were
updated within 12 months of the analysis date in 86% of cases. Only
8 of 393 (2%) patients or carriers were lost to follow-up.
Outcome measures
The primary study end points were ‘age at onset of RRT’ and ‘life
expectancy.’ Secondary end points included the decrease of
proteinuria after initiation of ACEi therapy (determined as g
protein per day or per g creatinine in children, depending on the
center’s preference), proportion of patients with a clinical diagnosis
of hypertension (defined as 495th percentile for gender, age, and
height in children), proportion of patients experiencing side effects
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from ACE inhibitors, defined as acute renal failure (doubling of
serum creatinine), angioedema, hyperkalemia 45.0mmol/l, dry
cough, symptomatic hypotension (orthostatic collapse), and others,
and death from all causes. For maximum transparency in the
evaluation of side effects, heterozygous carriers of Alport mutations
were included in analysis of side effects, but excluded from all other
analyses.
Intervention
The study investigated the treatment effects of ACE inhibitors; the
control intervention was no therapy. The most commonly used ACE
inhibitors were ramipril (0.025–0.1mg/kg bodyweight) and enalapril
(0.125–1.0mg/kg bodyweight). Patients were categorized depending
on renal function at initiation of therapy. Initiation of therapy was
defined as:
K T-I starts at patients with microhematuria only (usually at birth)
or microalbuminuria (30–300mg protein per day or per g
creatinine in children).
K T-II starts at patients with proteinuria 40.3 g/day or per g
creatinine.
K T-III starts at patients with CKD stages III and IV.
K noTmeans no therapy until CKD stage V, on renal replacement
therapy.
Statistical analysis
Distributions of continuous variables are summarized by means and
95% confidence intervals, whereas frequencies and percentages are
given for categorical (including binary) variables. The primary
efficacy end points ‘age at onset of RRT’ and ‘life expectancy’ are
censored in some patients as not all patients included in the analyses
have started RRT (or died). Therefore, appropriate statistical
methods for censored time-to-event data were used including the
Kaplan–Meier estimator and the log-rank test.30 Life expectancy was
defined as lifespan from birth to death. Only patients (irrespective of
their therapy group before end-stage renal failure) with unlimited
access to RRT were included in analysis of life expectancy. In the
analysis of the siblings, the paired data were analyzed using a
stratified version of the log-rank test.31 Median event times are
reported with 95% confidence intervals that are based on log–log-
transformed confidence intervals of the event probabilities. If the
confidence intervals of the event probabilities are too wide across all
observed event times because of small samples, the confidence limits
for the median cannot be determined. All analyses are of an
exploratory nature and therefore no correction for multiple testing
was applied. All reported P-values were two sided and those o0.05
were referred to as statistically significant. All inferential analyses
were carried out using SAS, version 9.2 (SAS Institute, Cary, NC).
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